Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

COVID-19 and sickle cell disease in Bahrain

Abdulkarim AbdulRahmana, Salman AlAib, Omar Yaghib, Mohammed Shabaanc, Sameer Ootoomc, Stephen L. Atkinb,*, Manaf AlQahtanib

a Bahrain National Taskforce to Combat COVID-19, Mohammed Bin Khalifa Cardiac Centre, Bahrain
b Bahrain National Taskforce to Combat COVID-19, Bahrain Defense Force Hospital, Bahrain
c Supreme Council of Health, Bahrain
d Royal College of Surgeons in Ireland-Bahrain, Bahrain

A R T I C L E   I N F O
Article history:
Received 23 May 2020
Received in revised form 22 September 2020
Accepted 22 September 2020

Keywords:
COVID-19
SARS-CoV-2
Sickle cell disease

A B S T R A C T
Introduction: Coronavirus disease 2019 (COVID-19) is caused by a newly identified strain of the coronavirus family that has been shown to affect the hemoglobin beta chain, the same chain that has sickle cell disease (SCD) mutation. This study was undertaken to see if COVID-19 infection increased disease severity in patients with SCD.

Methods: Mass screening of the Bahraini population was undertaken between February and April 2020. Results: A total of 38,092 Bahraini people were tested for COVID-19 during this period; 378 (1%) were SCD patients. Six patients with SCD had COVID-19 (1.6%): three remained asymptomatic, two had mild symptoms and one required oxygen therapy. The SCD patients had a similar average length of stay when compared with non-SCD COVID-19 patients (10.7 days).

Conclusion: The infection rate, clinical course and viral clearance seen for the SCD patients with COVID-19 were no different to those without SCD.

© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Coronavirus disease 2019 (COVID-19) is caused by a newly identified strain of the coronavirus family: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Anon, 2020) Virus isolation and nucleic acid sequencing have shown that the novel coronavirus is a positive-stranded RNA (Wenzhong and Huanlan, 2020a). It has been suggested that the virus acts through ACE2, CD147 and CD26 receptors on the erythrocytes, resulting in a hemoglobinopathy interaction with the hemoglobin molecule; viral ORF8 surface glycoproteins combine with porphyrin to form a complex with 1-beta chain of hemoglobin, with or without hemolysis forming a dysfunctional hemoglobin, resulting in decreased heme oxygen-carrying capacity (Wenzhong and Huanlan, 2020a; Liu and Li, 2020; Wenzhong and Huanlan, 2020b).

Sickle cell disease (SCD) is an inherited hemoglobinopathy due to a mutation in the hemoglobin-beta gene found on chromosome 11. SCD affects 1% of the Bahraini population (Al Arrayed and Haites, 1995) and causes the red blood cells to sickle, causing a sickle cell crisis that may result in hypoxic injury to organs. The prevalence of SCD in Bahrain has decreased from the 1980s when the prevalence was 2%, due to education and a premarital testing program that tests for both sickle cell and thalassemia (Al Arrayed and Haites, 1995). Couples with risk of passing on hemoglobinopathies are referred for genetic counselling. In addition, a screening program for SCD has been introduced, where all newborn babies are screened for the disease (Shaikha Al Arrayed et al., 2009). Sickle cell disease diagnosis is established by hemoglobin electrophoresis and confirmed by a positive sickling test result. Patients with SCD are all in a regular follow-up program and managed with disease modifying agents such as hydroxyurea. Patients are referred for hematopoietic stem cell transplantation when possible.

Infections may induce sickle cell crisis requiring hospital admission (Booth et al., 2010). Several anecdotal reports have suggested worse COVID-19 complications in SCD (McCluskey et al., 2020; Hussain et al., 2020; Beerens et al., 2020; De Luna et al., 2020). A review of the literature on COVID-19 and SCD cases highlighted that SARS-CoV-2 infection should be considered to be an important triggering factor of sickle cell crisis and that there are many unanswered questions, including the potential increased risk of SARS-CoV-2 infection in SCD and if there is a role for preventative red blood cell exchange (Sahu et al., 2020). This
study was undertaken to determine if patients with SCD are a high-risk group, as has been suggested (Roy et al., 2020).

Methods

Mass population screening for COVID-19, including mobile clinics, was established in Bahrain. In this cross-sectional study, all COVID-19 testing data on the Bahraini population was reviewed from the start of the screening in February until 25 April 2020. The SCD status of subjects was acquired from hospital medical records and the E-government authority of open data portals. Further details on the length of stay and time to viral clearance were collected from the medical records of all patients with COVID-19. The diagnostic test used for SARS-CoV-2 was real-time RT-PCR: all were tested for E gene and positive samples were confirmed after being tested for N gene and RdRp gene (from Tib Molbiol) (Corman et al., 2020). Viral clearance was defined as two RT-PCR-negative tests 24 h apart. Ethical permission was granted by the National Research Committee of COVID-19.

Statistical analysis

Statistical analysis was performed using the STATA statistical computer package (StataCorp 2013, Stata Statistical Software). Differences between the patients with and without SCD were compared by a two-way t-test.

Results

Table 1 shows the demographics between those with and without SCD. The Bahraini population is 689,714, and a total of 6933 (1%) Bahraini people are affected by SCD. During this period 38,092 Bahraini people were tested for COVID-19, of whom 378 (1%) were SCD patients. Of the 38,092 individuals tested for COVID-19, 696 (1.83%) were infected; 387 (1% of those tested) also had SCD, of whom six (1.6%) had COVID-19 (p = 0.55). Of the six SCD with COVID-19 (Table 2), three remained asymptomatic and one developed mild symptoms of an upper respiratory tract infection. Two patients developed moderate symptoms and one of them required oxygen therapy. These two patients did not require ventilator support or ICU care. The maximum length of stay was 12 days. All six patients were discharged; their average length of stay was 9.8 days. The SCD patients had a similar average length of stay when compared with non-SCD COVID-19 patients (10.7 days), which is the time to viral clearance (two RT-PCR negative tests 24 h apart) (p = 0.11, not significant).

Discussion

Whilst there were six patients with SCD who developed COVID-19 disease, it can be seen that severity of COVID-19 disease was no worse compared with those without SCD. The time to viral clearance was no different between those with and without SCD, with a similar hospital stay; further, in the course of the infection, one patient required oxygen therapy and none required ventilator support. In addition, no SCD patient suffered a sickle cell crisis as had been hypothesized, given that the SARS-CoV-2 virus may affect the hemoglobin beta chain (Wenzhong and Hualan, 2020a) and that infection may precipitate a crisis (Booth et al., 2010). Others have hypothesized that in beta-thalassemia, where there is a fault in hemoglobin beta-chain synthesis, this may result in immunity to SARS-CoV-2 infection (Lansiaux et al., 2020) and may therefore be protective, but that was not seen in the SCD patients who were studied.

At the time of writing, the prevalence of COVID-19 disease in Bahrain was approximately 0.1%, with 2464 documented cases. A total of 114,110 tests had been conducted, resulting about 71 tests per 1000 people. Of the 2464 cases, eight deaths had been recorded, 1189 cases had recovered and 1447 cases had been admitted. All COVID-19 cases had been admitted to either an isolated COVID-19 ICU, hospital or isolation facility, depending on the patients’ medical requirements.

The percentage of the tested SCD people (1%) reflected the overall population with SCD within the Bahraini community. 1.8% of all COVID-19 tested individuals in this study were positive, including those with and without SCD, suggesting that there is no increased infection rate in those with SCD. However, the main limitation of this observational study was the low number of SCD who had COVID-19 and the possibility of a type 2 statistical error due to low power.

In conclusion, the infection rate, clinical course and viral clearance seen for SCD patients with COVID-19 were no different to those without SCD. It is therefore encouraging that people with SCD are not at increased risk during the course of COVID-19 infection, nor at risk of a sickle cell crisis.

Ethics approval and consent to participate

The study was approved by the National Covid-19 Ethics Committee.

Consent for publication

All authors gave their consent for publication.

Availability of data and materials

All the data for this study will be made available upon reasonable request to the corresponding author.

Funding

None declared.

Conflict of interest

None declared.

Author contributions

AA and SA analyzed the data and wrote the manuscript. OY, MS and SA contributed to study design, collected, analyzed, and interpreted data and edited the manuscript. MA supervised data collection, analyzed data and edited the manuscript. SLA and SO interpreted data and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

Manaf Alqahtani is the guarantor of this work.

References

Al Arrayed S, Haites N. Features of Sickle-Cell Disease in Bahrain. 1995. https://apps.who.int/iris/handle/10665/117239.
Table 2
Characteristics of the six patients with sickle cell disease and SARS-CoV-2 infection.

| Age (years) | Gender | SCD genotype | Chief complaints | SARS-CoV2 PCR | Chest X-ray | Hb (g/dL) | WBC (x10^9/L) | CRP (mg/L) | Maximum oxygenation support | Management | Discharge day |
|-------------|--------|--------------|------------------|---------------|-------------|-----------|--------------|------------|-----------------------------|------------|--------------|
| 23          | Male   | HbSS         | Asymptomatic: tested positive on return from travel Fever, myalgia, cough and diarrhea | Positive | Normal | 17.1 | 3.28 | N/A | None | Observation alone | 10 |
| 40          | Male   | HbSS         | Asymptomatic: tested positive on return from travel Fever, myalgia, cough and diarrhea | Positive | Infiltrates | 7.4 | 13.73 | 137 | Nasal cannula 2 L O₂ | 10 |
| 52          | Male   | HbSS         | Asymptomatic: tested positive on return from travel Fever, myalgia, cough and diarrhea | Positive | Normal | 10.2 | 6.77 | 7.3 | None | Observation alone | 12 |
| 25          | Male   | HbSS         | Asymptomatic: tested positive on contact tracing Fever, myalgia, cough and diarrhea | Positive | Normal | 12.8 | 3.71 | 4.5 | None | Observation alone | 8 |
| 21          | Female | HbSS         | Infection: fever, loss of smell and taste | Positive | Normal | 13.8 | 4.61 | 4.22 | None | Supportive and IVF | 8 |
| 24          | Female | HbSS         | Infection: fever and myalgia | Positive | Normal | 8.5 | 11.63 | 1.48 | None | Antibiotics, supportive care | 9 |

Anon. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5(4):536–44.

Beerkens F, John M, Paliafito B, Corbett V, Edwards C, Tremblay D. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol 2020; PMID: 32243621.

Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. JID 2010;14(1): e2–e12.

Corman VM, Landt O, Kaiser M, Molkenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3).

De Luna G, Habibi A, Deux JP, Colard M, Pham Hung d’Alexandry d’Orengiani AL, Schlemmer F, et al. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol 2020;95(7):876–8.

Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. British J Haematol 2020;188(5):851–2.

Lansiaux E, Pébay P, Picard J-L, Son-Forget J. COVID-19: beta-thalassemia subjects immunised? Med Hypotheses 2020;109827.

Liu W, Li H. COVID-19 disease: ORF8 and surface glycoprotein inhibit heme metabolism by binding to porphyrin. ChemRxiv 2020c. doi:http://dx.doi.org/10.26434/chemrxiv.

McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID-19 infection and sickle cell disease: a UK centre experience. British J Haematol 2020;190(2):e57–8.

Roy NRA, Telfer P, Eleftheriou P, de la Fuente J, Drasar E, Shah F, et al. Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. British J Haematol. 2020;189(4):635–9.

Sahu KK, Siddiqui AD, Cerny J. Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. Br J Haematol 2020;190(2):e86–9.

Shaikha Al Arayed M, Amani Al Hajeri M, CABFM I. Clients’ satisfaction of the premarital counseling service in Bahrain. Bahrain Med Bull 2009;31(3).

Wenzhong L, Hualan L. COVID-19: attacks the 1-beta Chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv 2020a;. Preprint https://doi.org/1026434/chemrxiv.11938173:v6.

Wenzhong L, Hualan L. COVID-19 disease: ORF8 and surface glycoprotein inhibit heme metabolism by binding to porphyrin. ChemRxiv 2020b;. Preprint https://doi.org/1026434/chemrxiv.11938173:v3.